课题基金 / 基金详情

DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS

DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
与抗叶酸药物组合的药物协同作用
批准号:
3189420
负责人:
JOHN H GALIVAN
金额:
$7.99万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-04-01 至 1991-03-31

项目摘要

项目成果

JOHN H GALIVAN的其他基金

相似基金

相关文献

中文摘要
翻译
所提出的研究是针对生长抑制和 抗叶酸剂组合的机理评价 在培养物中对肝癌细胞表现出协同作用。 初步研究表明二氢叶酸还原酶 (DHFR)抑制剂可以与基于叶酸的药物组合。 胸苷酸合成酶(TS)抑制剂(N10-丙炔基-5,8- 二去氮唑草酯,PDDF)以产生协同肿瘤细胞生长 抑制和毒性。 目前最有效的DHFR 与PDDF组合的抑制剂是脂溶性抗叶酸剂, 例如甲氧苄氨蝶呤或三甲曲沙。 我们建议 评估其他DHFR抑制剂,以确定哪些是 哪种药物最有效,哪种药物最有效。 的 协同组合的一般性将在以下试验中进行测试: 其他肿瘤细胞系统。 实验方法将是 通过测量协同效应来评估抑制 结合生长和克隆测定。 代谢 协同组合的抑制作用将通过 测量处理的细胞中从头胸苷酸生物合成。 的 观察到胸苷可以防止基于 生长抑制表明,轻度抑制浓度的 DHFR抑制剂使细胞对PDDF敏感。 这可能是 由5,10-亚甲基四氢叶酸的减少和 增加dUMP,这有利于抑制的形成 PDDF-TS-dUMP三元复合物。 详细的机械 分析了这两类药物的协同作用, 将制备抗叶酸剂。 现阶段的做法是, 该研究将检查DHFR和TS的影响 抑制剂对TS底物水平的影响。 此外 目标酶的功能量和 将检查协同抑制期间与TS结合的PDDF。 独特药物相互作用的其他原因合理, 这些问题将根据 提出了机制研究。 希望能理解 这一机制将导致更多的知识, 抗叶酸剂在肿瘤治疗中的应用及进展 这些药物组合的潜力。
英文摘要
The proposed study is directed at a growth inhibitory and mechanistic evaluation of combinations of antifolates which exhibit synergy with each other against hepatoma cells in culture. The preliminary studies have shown the dihydrofolate reductase (DHFR) inhibitors can be combined with a folate based thymidylate synthase (TS) inhibitor (N10-propartyl-5,8- dideazafolate, PDDF) to yield synergistic tumor cell growth inhibition and toxicity. Currently the most effective DHFR inhibitors in combination with PDDF are the lipid soluble antifols such as metoprin or trimetrexate. We propose to make evaluations of other DHFR inhibitors to determine which are the most effective and which drug timing is the most effective. The generality of the synergistic combinations are to be tested in other tumor cell systems. The experimental approach will be to evaluate the inhibition by measuring the effects of synergistic combination with outgrowth and clonal assays. Metabolic inhibition by the synergistic combinations will be evaluated by measuring de novo thymidylate biosynthesis in treated cells. The observation that thymidine can protect against combination based growth inhibition suggests that mildly inhibitory concentrations of DHFR inhibitors are sensitizing the cells to PDDF. This could be accounted by a reduction in 5,10-methylenetetrahydrofolate and increase in dUMP, which favors the formation of an inhibited PDDF-TS-dUMP ternary complex. A detailed mechanistic analysis of the synergistic interaction of the two classes of antifolates will be made. The approach in the current phase of the study will be to examine the effects of the DHFR and TS inhibitors on levels of substrates for TS. In addition the functional amounts of the target enzymes and the amounts of PDDF bound to TS during synergistic inhibition will be examined. Other causes for the unique drug interaction are plausible and these will be considered depending upon the outcome of the proposed mechanistic studies. It is hoped that an understanding of this mechanism will result in more knowledge about the use of the antifolates in treatment of neoplasms and the development of the potential for combination of these agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
WADSWORTH CTR: INFECTIOUS DIS, WEST NILE, AIDS, MALARIA, TB, BIOTERRORISM, LYME
  • 批准号:
    6794518
  • 项目类别:
  • 资助金额:
    $199.93万
  • 财政年份:
    2002
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
  • 批准号:
    3189422
  • 项目类别:
  • 资助金额:
    $8.26万
  • 财政年份:
    1988
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
  • 批准号:
    3189421
  • 项目类别:
  • 资助金额:
    $8.01万
  • 财政年份:
    1988
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
VITAMIN FUNCTION IN LIVER STUDIED IN VITRO
  • 批准号:
    3172035
  • 项目类别:
  • 资助金额:
    $11.1万
  • 财政年份:
    1984
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
海外基金